KNSA
Kiniksa Pharmaceuticals, Ltd. (KNSA) 10Y Growth Potential Analysis (2026)
Overall Score
Growth
Kiniksa continues to show solid revenue and earnings growth potential supported by a 54.5% gross margin and 13.1% EBIT margin.
Return on invested capital is positive at 9.7%, indicating the business is generating acceptable returns on capital as it scales.
Profitability
Net margin is 9.6% and operating cash flow margin is 22.0%, showing the company is now consistently profitable on both an accounting and cash basis.
Free cash flow conversion is strong, with free cash flow nearly matching operating cash flow and capex remaining minimal.
Financial Health
The balance sheet is very strong with a current ratio of 3.9 and net debt to EBITDA of -1.49, indicating net cash.
Debt levels are negligible, with debt-to-equity at 0.01 and debt-to-assets below 1.0%, giving the company substantial financial flexibility.
Valuation
Valuation remains demanding at 6.9x EV/sales and 32.5x price to free cash flow, which limits upside if growth slows.
The PEG ratio is low, but the absolute multiples still imply the market is pricing in continued execution.
Future Outlook
The company has room to compound over the next decade if it sustains margin expansion and converts revenue growth into durable free cash flow.
A strong liquidity position and low leverage support continued investment in growth initiatives without near-term financing pressure.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Kiniksa Pharmaceuticals, Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.